Annika Fendler

Aug 24, 2023 | frontiersin.org | Housheng Hansen |Yafeng Ma |Dimple Chakravarty |Annika Fendler

MainTreatment options for metastatic lesions of prostate cancer (PCa) are limited, and resistance to androgen signalling inhibitors (ASI) is ultimately inevitable (1–3). Detecting aggressive disease while it is still manageable and understanding the underlying biology are clinical imperatives. The standard invasive tissue biopsy procedure for PCa diagnosis poses a risk to the patient (4), is limited in the early stages of disease (5), and is impractical for longitudinal disease monitoring.